Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link



Dow Jones Industrial Average



) is trading up 15 points at 16,024 as of Friday, Nov 22, 2013, 11:35 a.m. ET. During this time, 131.4 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 379.4 million. The NYSE advances/declines ratio sits at 1,437 issues advancing vs. 1,443 declining with 136 unchanged.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be



TST Recommends


), which is sporting a 30-cent gain (+0.6%) bringing the stock to $48.92. This single gain is lifting the Dow Jones Industrial Average by 2.27 points or roughly accounting for 15.1% of the Dow's overall gain. Volume for Merck currently sits at 7.1 million shares traded vs. an average daily trading volume of 14 million shares.

Merck has a market cap of $140.63 billion and is part of the health care sector and drugs industry. Shares are up 18.8% year to date as of Thursday's close. The stock's dividend yield sits at 3.6%.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company has a P/E ratio of 32.3, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Merck as a


. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more